Download PDF
Am J Perinatol 2022; 39(S 01): S31-S41
DOI: 10.1055/s-0042-1758858
Review Article

Maternal Origins of Neonatal Infections: What Do Obstetrician–Gynecologist Should/Could Do?

Chiara Germano   *
1   Department of Maternal, Neonatal and Infant Medicine, University Hospital “Degli Infermi,” Ponderano, Italy
2   Department of Surgical Sciences, University of Turin, Turin, Italy
,
Alessandro Messina   *
2   Department of Surgical Sciences, University of Turin, Turin, Italy
,
Alessio Massaro
2   Department of Surgical Sciences, University of Turin, Turin, Italy
3   Department of Surgical Sciences, Sant'Anna Hospital, University of Turin, Turin, Italy
,
Rossella Attini
3   Department of Surgical Sciences, Sant'Anna Hospital, University of Turin, Turin, Italy
,
Livio Leo
4   Department of Gynecology and Obstetrics, Hopital Beauregard, AUSL Valleè d'Aoste, Aosta, Italy
,
Paolo Manzoni
1   Department of Maternal, Neonatal and Infant Medicine, University Hospital “Degli Infermi,” Ponderano, Italy
,
Bianca Masturzo
1   Department of Maternal, Neonatal and Infant Medicine, University Hospital “Degli Infermi,” Ponderano, Italy
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Neonatal infections are responsible for 20% of neonatal deaths yearly. In this review, we focused on the origins of the commoner neonatal infections, and we define the role of obstetricians. Regarding group B Streptococcus, a key measure for the prevention of neonatal infection is the vaginal–rectal culture screening at term pregnancy. Intravenous penicillin is the first-line prophylaxis at the start of labor, with intravenous ampicillin as an alternative. First-generation cephalosporins or clindamycin are recommended in case of penicillin allergy. Concerning urinary tract infections (UTIs), guidelines recommend complete urinalysis and urine culture in the first trimester of pregnancy for the screening of asymptomatic bacteriuria. For lower UTIs, guidelines recommend nitrofurantoin as first-choice antibiotic. Amoxicillin or cefalexin are second-line antibiotics. For upper UTIs, guidelines recommend cephalexin per os as first line. Candida spp. colonization affects 20% of pregnant women; however, congenital fetal candidosis and Candida amnionitis are rare. First-line treatment in case of symptomatic vaginitis during pregnancy or asymptomatic colonization during the third trimester is vaginal clotrimazole. Fluconazole is not approved in pregnancy, especially during the first trimester. Genital mycoplasmas colonization during pregnancy is usually asymptomatic and associated with bacterial vaginosis. Colonization is related to neonatal respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), pneumonia, chorioamnionitis, and sepsis. Macrolides are the first-line treatment along with lactobacillus supplementation. In cases of preterm premature rupture of membranes or preterm labor, ceftriaxone, clarithromycin, and metronidazole are required to prevent intra-amniotic infection. Intra-amniotic infection affects 1 to 5% of deliveries at term and one-third of preterm ones and is associated with perinatal death, early-onset neonatal sepsis, RDS, BPD, pneumonia, meningitis, and prematurity-related diseases. Guidelines recommend a combination of ampicillin and gentamicin, and in case of caesarean section, an additional dose of clindamycin or metronidazole is required. In conclusion, obstetricians should be aware that the treatment of maternal infection during pregnancy can prevent potentially lethal infections in the newborn.

Key Points

  • Part of neonatal infections starts from maternal infections that must be treated during pregnancy.

  • Streptococcus group B and asymptomatic bacteriuria should be investigated in pregnancy and treated.

  • Mycoplasma and ureaplasma vaginal colonization during pregnancy is related to negative neonatal outcomes.

Keywords

neonatal infections - maternal infections - genitourinary and gastrointestinal tracts - pregnancy - early-onset neonatal sepsis - late-onset sepsis

* These authors equally contributed to this paper.




Publication History

Article published online:
19 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Liu L, Johnson HL, Cousens S, Perin J, Scott S. et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012; 79 (9832): 2151-2161
    CrossrefPubMedGoogle Scholar
  • 2 Schrag SJ, Farley MM, Petit S. et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. Pediatrics 2016; 138 (06) e20162013
    CrossrefPubMedGoogle Scholar
  • 3 Procianoy RS, Silveira RC. The challenges of neonatal sepsis management. J Pediatr (Rio J) 2020; 96 (suppl 1): 80-86
    CrossrefPubMedGoogle Scholar
  • 4 ACOG.. Prevention of group b streptococcal early-onset disease in newborns. ACOG Committee Opinion. Obstet Gynecol 2020;797
    PubMedGoogle Scholar
  • 5 Vornhagen J, Adams Waldorf KM, Rajagopal L. Perinatal group B Streptococcal Infections: virulence factors, immunity, and prevention strategies. Trends Microbiol 2017; 25 (11) 919-931
    CrossrefPubMedGoogle Scholar
  • 6 Brown AP, Denison FC. Selective or universal screening for GBS in pregnancy (review). (review) Early Hum Dev 2018; 126: 18-22
    CrossrefPubMedGoogle Scholar
  • 7 Turrentine MA, Greisinger AJ, Brown KS, Wehmanen OA, Mouzoon ME. Duration of intrapartum antibiotics for group B Streptococcus on the diagnosis of clinical neonatal sepsis. Infect Dis Obstet Gynecol 2013; 2013: 525878
    CrossrefPubMedGoogle Scholar
  • 8 Fairlie T, Zell ER, Schrag S. Effectiveness of intrapartum antibiotic prophylaxis for prevention of early-onset group B streptococcal disease. Obstet Gynecol 2013; 121 (03) 570-577
    CrossrefPubMedGoogle Scholar
  • 9 Schrag SJ, Zywicki S, Farley MM. et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342 (01) 15-20
    CrossrefPubMedGoogle Scholar
  • 10 Matuszkiewicz-Rowińska J, Małyszko J, Wieliczko M. Urinary tract infections in pregnancy: old and new unresolved diagnostic and therapeutic problems. Arch Med Sci 2015; 11 (01) 67-77
    CrossrefPubMedGoogle Scholar
  • 11 Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis 2013; 20 (03) 209-214
    CrossrefPubMedGoogle Scholar
  • 12 Sharami SH, Afrakhteh M, Shakiba M. Urinary tract infections in pregnant women with bacterial vaginosis. J Obstet Gynaecol 2007; 27 (03) 252-254
    CrossrefPubMedGoogle Scholar
  • 13 Hillebrand L, Harmanli OH, Whiteman V, Khandelwal M. Urinary tract infections in pregnant women with bacterial vaginosis. Am J Obstet Gynecol 2002; 186 (05) 916-917
    CrossrefPubMedGoogle Scholar
  • 14 Sheiner E, Mazor-Drey E, Levy A. Asymptomatic bacteriuria during pregnancy. J Matern Fetal Neonatal Med 2009; 22 (05) 423-427
    CrossrefPubMedGoogle Scholar
  • 15 Szweda H, Jóźwik M. Urinary tract infections during pregnancy—an updated overview. Dev Period Med 2016; 4: 263-272
    PubMedGoogle Scholar
  • 16 Antenatal Care for Uncomplicated Pregnancies. London, United Kingdom: National Institute for Health and Care Excellence (NICE); 2019
    Google Scholar
  • 17 Widmer M, Lopez I, Gülmezoglu AM, Mignini L, Roganti A. Duration of treatment for asymptomatic bacteriuria during pregnancy. Cochrane Database Syst Rev 2015; (11) CD000491
    PubMedGoogle Scholar
  • 18 Vazquez JC, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database Syst Rev 2011; (01) CD002256
    PubMedGoogle Scholar
  • 19 National Institute for Health and Care Excellence (NICE) Urinary tract infection (lower): Antimicrobial prescribing. Clinical guideline [NG109] 2018. Accessed December 1, 2022 at: https://www.nice.org.uk/guidance/ng109
    PubMedGoogle Scholar
  • 20 Park JC, Buono D, Smith DK. et al; HIV Epidemiology Research Study (HERS) group. Urinary tract infections in women with or at risk for human immunodeficiency virus infection. Am J Obstet Gynecol 2002; 187 (03) 581-588
    CrossrefPubMedGoogle Scholar
  • 21 Glaser AP, Schaeffer AJ. Urinary tract infection and bacteriuria in pregnancy. Urol Clin North Am 2015; 42 (04) 547-560
    CrossrefPubMedGoogle Scholar
  • 22 Thomas AA, Thomas AZ, Campbell SC, Palmer JS. Urologic emergencies in pregnancy. Urology 2010; 76 (02) 453-460
    CrossrefPubMedGoogle Scholar
  • 23 Wing DA, Fassett MJ, Getahun D. Acute pyelonephritis in pregnancy: an 18-year retrospective analysis. Am J Obstet Gynecol 2014; 210 (03) 219.e1-219.e6
    CrossrefPubMedGoogle Scholar
  • 24 National Institute for Health and Care Excellence (NICE). Pyelonephritis (acute): antimicrobial prescribing. Guidance and guidelines. [NG111] 2018. Accessed December 1, 2022 at: https://www.nice.org.uk/guidance/ng111
    PubMedGoogle Scholar
  • 25 Schneeberger C, Geerlings SE, Middleton P, Crowther CA. Interventions for preventing recurrent urinary tract infection during pregnancy. Cochrane Database Syst Rev 2015; (07) CD009279
    PubMedGoogle Scholar
  • 26 Warzecha D, Pietrzak B, Urban A, Wielgoś M. How to avoid drug resistance during treatment and prevention of urinary tract infections. Prz Menopauzalny 2021; 20 (04) 217-221
    PubMedGoogle Scholar
  • 27 Farr A, Effendy I, Frey Tirri B. et al. Guideline: vulvovaginal candidosis (AWMF 015/072, level S2k). Mycoses 2021; 64 (06) 583-602
    CrossrefPubMedGoogle Scholar
  • 28 Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis 2018; 18 (11) e339-e347
    CrossrefPubMedGoogle Scholar
  • 29 Yano J, Peters BM, Noverr MC, Fidel Jr PL. Novel mechanism behind the immunopathogenesis of vulvovaginal candidiasis: “neutrophil anergy”. Infect Immun 2018; 86 (03) e00684-e17
    CrossrefPubMedGoogle Scholar
  • 30 Marschalek J, Farr A, Kiss H. et al. Risk of vaginal infections at early gestation in patients with diabetic conditions during pregnancy: a retrospective cohort study. PLoS One 2016; 11 (05) e0155182
    CrossrefPubMedGoogle Scholar
  • 31 Yano J, Sobel JD, Nyirjesy P. et al. Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes. BMC Womens Health 2019; 19 (01) 48
    CrossrefPubMedGoogle Scholar
  • 32 Zhang X, Liao Q, Wang F, Li D. Association of gestational diabetes mellitus and abnormal vaginal flora with adverse pregnancy outcomes. Medicine (Baltimore) 2018; 97 (34) e11891
    CrossrefPubMedGoogle Scholar
  • 33 Aagaard K, Riehle K, Ma J. et al. A metagenomic approach to characterization of the vaginal microbiome signature in pregnancy. PLoS One 2012; 7 (06) e36466
    CrossrefPubMedGoogle Scholar
  • 34 Santos CMA, Pires MCV, Leão TL. et al. Selection of Lactobacillus strains as potential probiotics for vaginitis treatment. Microbiology 2016;162(07): Doi: org/10.1099/mic.0.000302
    PubMedGoogle Scholar
  • 35 Gupta P, Faridi MM, Rawat S, Sharma P. Clinical profile and risk factors for oral candidosis in sick newborns. Indian Pediatr 1996; 33 (04) 299-303
    PubMedGoogle Scholar
  • 36 Roberts CL, Rickard K, Kotsiou G, Morris JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent preterm birth: an open-label pilot randomized controlled trial. BMC Pregnancy Childbirth 2011; 11: 18
    CrossrefPubMedGoogle Scholar
  • 37 Farr A, Kiss H, Holzer I, Husslein P, Hagmann M, Petricevic L. Effect of asymptomatic vaginal colonization with Candida albicans on pregnancy outcome. Acta Obstet Gynecol Scand 2015; 94 (09) 989-996
    CrossrefPubMedGoogle Scholar
  • 38 Mølgaard-Nielsen D, Svanström H, Melbye M, Hviid A, Pasternak B. Association between use of oral fluconazole during pregnancy and risk of spontaneous abortion and stillbirth. JAMA 2016; 315 (01) 58-67
    CrossrefPubMedGoogle Scholar
  • 39 Howley MM, Carter TC, Browne ML, Romitti PA, Cunniff CM, Druschel CM. National Birth Defects Prevention Study. Fluconazole use and birth defects in the national birth defects prevention study. Am J Obstet Gynecol 2016; 214 (05) 657.e1-657.e9
    CrossrefPubMedGoogle Scholar
  • 40 Mølgaard-Nielsen D, Pasternak B, Hviid A. Use of oral fluconazole during pregnancy and the risk of birth defects. N Engl J Med 2013; 369 (09) 830-839
    CrossrefPubMedGoogle Scholar
  • 41 Ma C, Du J, Dou Y. et al. The associations of genital mycoplasmas with female infertility and adverse pregnancy outcomes: a systematic review and meta-analysis. Reprod Sci 2021; 28 (11) 3013-3031
    CrossrefPubMedGoogle Scholar
  • 42 Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of pathogenic mycoplasmas. Microb Pathog 2000; 29 (05) 301-309
    CrossrefPubMedGoogle Scholar
  • 43 Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18 (04) 757-789
    CrossrefPubMedGoogle Scholar
  • 44 Donders GGG, Ruban K, Bellen G, Petricevic L. Mycoplasma/Ureaplasma infection in pregnancy: to screen or not to screen. J Perinat Med 2017; 45 (05) 505-515
    PubMedGoogle Scholar
  • 45 Ruzman N, Miskulin M, Rudan S, Bosnjak Z. The prevalence and the risk factors of the cervical colonization by the genital mycoplasmas among pregnant women from Eastern Croatia. Coll Antropol 2013; 37 (01) 135-140
    PubMedGoogle Scholar
  • 46 Motomura K, Romero R, Xu Y. et al. Intra-amniotic infection with Ureaplasma parvum causes preterm birth and neonatal mortality that are prevented by treatment with clarithromycin. MBio 2020; 11 (03) e00797-e20
    CrossrefPubMedGoogle Scholar
  • 47 Peuchant O, Le Roy C, Desveaux C. et al. Screening for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium should it be integrated into routine pregnancy care in French young pregnant women?. Diagn Microbiol Infect Dis 2015; 82 (01) 14-19
    CrossrefPubMedGoogle Scholar
  • 48 Martius J, Eschenbach DA. The role of bacterial vaginosis as a cause of amniotic fluid infection, chorioamnionitis and prematurity—a review. Arch Gynecol Obstet 1990; 247 (01) 1-13
    CrossrefPubMedGoogle Scholar
  • 49 Taylor-Robinson D, McCormack WM. The genital mycoplasmas (second of two parts). N Engl J Med 1980; 302 (19) 1063-1067
    CrossrefPubMedGoogle Scholar
  • 50 Gravett MG, Eschenbach DA. Possible role of Ureaplasma urealyticum in preterm premature rupture of the fetal membranes. Pediatr Infect Dis 1986; 5 (6, suppl): S253-S257
    CrossrefPubMedGoogle Scholar
  • 51 Harada K, Tanaka H, Komori S. et al. Vaginal infection with Ureaplasma urealyticum accounts for preterm delivery via induction of inflammatory responses. Microbiol Immunol 2008; 52 (06) 297-304
    CrossrefPubMedGoogle Scholar
  • 52 Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319 (15) 972-978
    CrossrefPubMedGoogle Scholar
  • 53 Xu YP, Hu JM, Huang YQ, Shi LP. Maternal Ureaplasma exposure during pregnancy and the risk of preterm birth and BPD: a meta-analysis. Arch Gynecol Obstet 2022; 306 (06) 1863-1872
    CrossrefPubMedGoogle Scholar
  • 54 Gray DJ, Robinson HB, Malone J, Thomson Jr RB. Adverse outcome in pregnancy following amniotic fluid isolation of Ureaplasma urealyticum . Prenat Diagn 1992; 12 (02) 111-117
    CrossrefPubMedGoogle Scholar
  • 55 Waites KB, Crouse DT, Cassell GH. Systemic neonatal infection due to Ureaplasma urealyticum . Clin Infect Dis 1993; 17 (suppl 1): S131-S135
    CrossrefPubMedGoogle Scholar
  • 56 Sprong KE, Mabenge M, Wright CA, Govender S. Ureaplasma species and preterm birth: current perspectives. Crit Rev Microbiol 2020; 46 (02) 169-181
    CrossrefPubMedGoogle Scholar
  • 57 Chu A, de St Maurice A, Sim MS, Kallapur SG. Neonatal mycoplasma and ureaplasma infections. Pediatr Ann 2020; 49 (07) e305-e312
    PubMedGoogle Scholar
  • 58 Cassell GH, Waites KB, Crouse DT. et al. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet 1988; 2 (8605): 240-245
    CrossrefPubMedGoogle Scholar
  • 59 Bartkeviciene D, Opolskiene G, Bartkeviciute A. et al. The impact of Ureaplasma infections on pregnancy complications. Libyan J Med 2020; 15 (01) 1812821
    CrossrefPubMedGoogle Scholar
  • 60 Lyon A. Chronic lung disease of prematurity. The role of intra-uterine infection. Eur J Pediatr 2000; 159 (11) 798-802
    CrossrefPubMedGoogle Scholar
  • 61 Viscardi RM, Hashmi N, Gross GW, Sun CC, Rodriguez A, Fairchild KD. Incidence of invasive ureaplasma in VLBW infants: relationship to severe intraventricular hemorrhage. J Perinatol 2008; 28 (11) 759-765
    CrossrefPubMedGoogle Scholar
  • 62 Brus F, van Waarde WM, Schoots C, Oetomo SB. Fatal ureaplasmal pneumonia and sepsis in a newborn infant. Eur J Pediatr 1991; 150 (11) 782-783
    CrossrefPubMedGoogle Scholar
  • 63 Sethi S, Sharma M, Narang A, Aggrawal PB. Isolation pattern and clinical outcome of genital mycoplasma in neonates from a tertiary care neonatal unit. J Trop Pediatr 1999; 45 (03) 143-145
    CrossrefPubMedGoogle Scholar
  • 64 Rao RP, Ghanayem NS, Kaufman BA, Kehl KS, Gregg DC, Chusid MJ. Mycoplasma hominis and Ureaplasma species brain abscess in a neonate. Pediatr Infect Dis J 2002; 21 (11) 1083-1085
    CrossrefPubMedGoogle Scholar
  • 65 Kasper DC, Mechtler TP, Böhm J. et al. In utero exposure to Ureaplasma spp. is associated with increased rate of bronchopulmonary dysplasia and intraventricular hemorrhage in preterm infants. J Perinat Med 2011; 39 (03) 331-336
    CrossrefPubMedGoogle Scholar
  • 66 Carey JC, Blackwelder WC, Nugent RP. et al; The Vaginal Infections and Prematurity Study Group. Antepartum cultures for Ureaplasma urealyticum are not useful in predicting pregnancy outcome. Am J Obstet Gynecol 1991; 164 (03) 728-733
    CrossrefPubMedGoogle Scholar
  • 67 Donders GG, Van Bulck B, Caudron J, Londers L, Vereecken A, Spitz B. Relationship of bacterial vaginosis and mycoplasmas to the risk of spontaneous abortion. Am J Obstet Gynecol 2000; 183 (02) 431-437
    CrossrefPubMedGoogle Scholar
  • 68 De Francesco MA, Caracciolo S, Bonfanti C, Manca N. Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years. J Infect Chemother 2013; 19 (04) 621-627
    CrossrefPubMedGoogle Scholar
  • 69 Lee SJ, Ahn JW, Lee JY, Lee SH, Roh HJ, Kwon YS. Maternal azithromycin administration eradicates intra-amniotic Ureaplasma infection: the first human case report. J Obstet Gynaecol 2016; 36 (02) 259-260
    CrossrefPubMedGoogle Scholar
  • 70 Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how?. Clin Infect Dis 2011; 53 (suppl 3): S129-S142
    CrossrefPubMedGoogle Scholar
  • 71 Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol 2016; 30 (10) 1650-1656
    CrossrefPubMedGoogle Scholar
  • 72 Oh KJ, Romero R, Park JY. et al. Evidence that antibiotic administration is effective in the treatment of a subset of patients with intra-amniotic infection/inflammation presenting with cervical insufficiency. Am J Obstet Gynecol 2019; 221 (02) 140.e1-140.e18
    CrossrefPubMedGoogle Scholar
  • 73 Yoon BH, Romero R, Park JY. et al. Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes. Am J Obstet Gynecol 2019; 221 (02) 142.e1-142.e22
    Google Scholar
  • 74 Lee J, Romero R, Kim SM. et al. A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM. J Matern Fetal Neonatal Med 2016; 29 (05) 707-720
    CrossrefPubMedGoogle Scholar
  • 75 Stafford GP, Parker JL, Amabebe E. et al. Spontaneous preterm birth is associated with differential expression of vaginal metabolites by lactobacilli-dominated microflora. Front Physiol 2017; 8: 615
    CrossrefPubMedGoogle Scholar
  • 76 Daniele M, Ruiz F, Pascual L, Barberis L. Ureaplasma urealyticum and Mycoplasma hominis sensitivity to bacteriocins produced by two Lactobacilli strains. Curr Microbiol 2011; 63 (04) 360-365
    CrossrefPubMedGoogle Scholar
  • 77 Higgins RD, Saade G, Polin RA. et al; Chorioamnionitis Workshop Participants. Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. Obstet Gynecol 2016; 127 (03) 426-436
    CrossrefPubMedGoogle Scholar
  • 78 Yoon BH, Romero R, Moon JB. et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2001; 185 (05) 1130-1136
    CrossrefPubMedGoogle Scholar
  • 79 Kachikis A, Eckert LO, Walker C. et al; Brighton Collaboration Chorioamnionitis Working Group. Chorioamnionitis: case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2019; 37 (52) 7610-7622
    CrossrefPubMedGoogle Scholar
  • 80 Romero R, Schaudinn C, Kusanovic JP. et al. Detection of a microbial biofilm in intraamniotic infection. Am J Obstet Gynecol 2008; 198 (01) 135.e1-135.e5
    CrossrefPubMedGoogle Scholar
  • 81 Romero R, Miranda J, Chaiworapongsa T. et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Reprod Immunol 2014; 72 (05) 458-474
    Google Scholar
  • 82 Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance. Am J Obstet Gynecol 2015; 213 (4, suppl) S29-S52
    CrossrefPubMedGoogle Scholar
  • 83 Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. Am J Obstet Gynecol 1998; 179 (01) 194-202
    CrossrefPubMedGoogle Scholar
  • 84 Jain VG, Kong F, Kallapur SG. et al. IRAK1 is a critical mediator of inflammation-induced preterm birth. J Immunol 2020; 204 (10) 2651-2660
    CrossrefPubMedGoogle Scholar
  • 85 Venkatesh KK, Jackson W, Hughes BL, Laughon MM, Thorp JM, Stamilio DM. Association of chorioamnionitis and its duration with neonatal morbidity and mortality. J Perinatol 2019; 39 (05) 673-682 [ Erratum in: J Perinatol. 2019 Mar 7]
    CrossrefPubMedGoogle Scholar
  • 86 Beck C, Gallagher K, Taylor LA, Goldstein JA, Mithal LB, Gernand AD. Chorioamnionitis and risk for maternal and neonatal sepsis: a systematic review and meta-analysis. Obstet Gynecol 2021; 137 (06) 1007-1022
    CrossrefPubMedGoogle Scholar
  • 87 Pappas A, Kendrick DE, Shankaran S. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Chorioamnionitis and early childhood outcomes among extremely low-gestational-age neonates. JAMA Pediatr 2014; 168 (02) 137-147
    CrossrefPubMedGoogle Scholar
  • 88 Al-Haddad BJS, Oler E, Armistead B. et al. The fetal origins of mental illness. Am J Obstet Gynecol 2019; 221 (06) 549-562
    CrossrefPubMedGoogle Scholar
  • 89 Been JV, Lievense S, Zimmermann LJ, Kramer BW, Wolfs TG. Chorioamnionitis as a risk factor for necrotizing enterocolitis: a systematic review and meta-analysis. J Pediatr 2013; 162 (02) 236-42.e2
    CrossrefPubMedGoogle Scholar
  • 90 Committee Opinion No. Committee Opinion No. 712: intrapartum management of intraamniotic infection. Obstet Gynecol 2017; 130 (02) e95-e101
    CrossrefPubMedGoogle Scholar
  • 91 Gibbs RS, Dinsmoor MJ, Newton ER, Ramamurthy RS. A randomized trial of intrapartum versus immediate postpartum treatment of women with intra-amniotic infection. Obstet Gynecol 1988; 72 (06) 823-828
    CrossrefPubMedGoogle Scholar